{"title":"Logistics of Adopting <sup>177</sup>Lu-Vipivotide Tetraxetan Therapy in a Community-Based Hospital Setting.","authors":"Kathleen Marsh, Kayla Allickson, Amanda Jesz, Cheryl Hanson, Donna Newman, Erica Martin-Macintosh","doi":"10.2967/jnmt.124.268039","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, <sup>177</sup>Lu-vipivotide tetraxetan was U.S. Food and Drug Administration-approved for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. <b>Methods:</b> Although preliminary data for <sup>177</sup>Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating <sup>177</sup>Lu-vipivotide tetraxetan into non-academic-based clinical practices. <b>Results:</b> This article presents a multidisciplinary practice implementation workflow for <sup>177</sup>Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. <b>Conclusion:</b> The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically <sup>177</sup>Lu-vipivotide tetraxetan.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":" ","pages":"68-71"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of nuclear medicine technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2967/jnmt.124.268039","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, 177Lu-vipivotide tetraxetan was U.S. Food and Drug Administration-approved for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. Methods: Although preliminary data for 177Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating 177Lu-vipivotide tetraxetan into non-academic-based clinical practices. Results: This article presents a multidisciplinary practice implementation workflow for 177Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. Conclusion: The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically 177Lu-vipivotide tetraxetan.